<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03937661</url>
  </required_header>
  <id_info>
    <org_study_id>PRP - poor responders</org_study_id>
    <nct_id>NCT03937661</nct_id>
  </id_info>
  <brief_title>Ovarian Autologous Platelet-Rich Plasma Treatment in Poor Responders.</brief_title>
  <acronym>PRP</acronym>
  <official_title>Evaluation of Ovarian Rejuvenation in Poor Responders Following Autologous Platelet-rich Plasma Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genesis Athens Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genesis Athens Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autologous ovarian Platelet Rich Plasma (PRP) treatment may enable ovarian rejuvenation,
      increase of AMH levels, and improved oocyte retrieval yield in poor responders undergoing
      single IVF cycle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific prospective clinical investigation, aims to answer whether autologous Platelet
      reactivation of the ovarian tissue functionality.

      PRP is blood plasma prepared from fresh whole blood that has been enriched with platelets. It
      is collected from peripheral veins and contains several growth factors such as vascular
      endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth
      factor (PDGF), transforming growth factor (TGF) and other cytokines all of which stimulate
      tissue proliferation and growth. PRP has been employed in several medical conditions in
      Orthopedics, Dermatology, Ophthalmology for wound healing. It's efficacy in ovarian
      rejuvenation and reactivation and endometrial regeneration has not been fully elucidated.

      The aim of this study is to evaluate the effectiveness of ovarian PRP injection, in order to
      reactivate ovarian function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oocytes retrieved</measure>
    <time_frame>34-36 hours following hCG administration</time_frame>
    <description>Oocytes retrieved in OPU during IVF stimulation cycle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AMH levels</measure>
    <time_frame>3 months or until pregnancy achieved</time_frame>
    <description>Serum AMH levels per month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>6-7 weeks following last menstruation</time_frame>
    <description>Clinical pregnancy rate following IVF-ET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antral Follicular count</measure>
    <time_frame>5 days following menstruation</time_frame>
    <description>Antral Folliculal count in TVUS during stimulation protocol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ovary; Anomaly</condition>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Group PRP patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Poor responder women 35-47 years of age, receiving ovarian PRP treatment trying for a natural conception or prior to an IVF cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group - placebo patients</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Poor responder women 35-47 years of age, receiving ovarian placebo - Platelet Free Plasma (PFP), trying for a natural conception or prior to an IVF cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRP</intervention_name>
    <description>Autologous Platelet-rich Plasma injection into the ovaries.</description>
    <arm_group_label>Group PRP patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injected into the ovaries.</description>
    <arm_group_label>Control Group - placebo patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Poor Ovarian Response according to Bologna Criteria (fulfilling 2 out of 3 of the
        following)

          -  Age ≥ 40 years

          -  AMH &lt; 1.1 ng/ml OR AFC &lt; 7

          -  ≤ 3 oocytes with a conventional stimulation protocol)

        Exclusion Criteria:

          -  Cycle irregularities

          -  Current diagnosis of cancer

          -  Amenorrhea

          -  Partner's azoospermia

          -  PGD cycles

          -  Ovarian inaccessibility

          -  Endocrinologic disorders (Thyroid Dysfunction, Diabetes mellitus, Metabolic syndrome),

          -  BMI&gt;30 kg/m2

          -  Systematic autoimmune disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>47 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mara Simopoulou, PhD</last_name>
    <phone>+306979234100</phone>
    <email>marasimopoulou@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agni Pantou, MD, PhD Candidate</last_name>
    <phone>+306974447702</phone>
    <email>agni.pantou@genesisathens.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Genesis AC</name>
      <address>
        <city>Athens</city>
        <zip>15232</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agni Pantou, MD, PhD Candidate</last_name>
      <email>agni.pantou@genesisathens.gr</email>
    </contact>
    <investigator>
      <last_name>Agni Pantou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Konstantinos Pantos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

